Nyxoah SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 13, 2025, reports on a series of capital raising transactions by Nyxoah SA, a Belgian company developing the Genio system for obstructive sleep apnoea (OSA) treatment. The filing details three concurrent financing initiatives: a Private Placement of ordinary shares, a Registered Direct Offering (RDO) of ordinary shares, and a Notes Offering of convertible senior unsecured notes.
Key Financial Metrics and Capital Structure
The filing outlines significant capital inflows expected to close on or about November 18, 2025:
- Private Placement: Sale of ordinary shares at €4.00 per share for aggregate gross proceeds of approximately €17.0 million.
- Registered Direct Offering (RDO): Sale of ordinary shares at US$4.6304 per share for aggregate gross proceeds of approximately US$5.6 million.
- Notes Offering: Sale of up to €45.0 million in aggregate principal amount of amortizing senior unsecured convertible notes at an 8.0% original issue discount. Assuming full issuance, gross proceeds are expected to be approximately €41.4 million.
- Debt Structure: The Notes bear interest at 6.5% per annum, payable quarterly. They rank senior to all other unsecured debt but are subordinated to the Company's existing credit facility with the European Investment Bank (EIB).
The filing does not provide historical revenue, profit, cash flow, or margin data for the reporting period.
Material Changes and Transaction Terms
The primary material change is the expansion of the Company's capital base through equity and debt instruments. Key terms include:
- Notes Amortization: The Notes will amortize in 12 quarterly installments. The Company may pay in cash (at 103% of the amount) or in ordinary shares (Amortization Shares) priced at the lower of the conversion price or 90% of the reference lowest daily market price.
- Conversion Rights: The First Tranche Notes have an initial conversion price of 125% of the Private Placement share price. The Second Tranche Notes have a conversion price of 125% of the market price at issuance. Conversion prices are subject to reset if the Company raises €2.0 million or more in equity.
- Second Tranche Conditions: Issuance of the Second Tranche Notes (€22.5 million) is contingent on the Company maintaining a Last Market Capitalization and Average Market Capitalization of at least €240.0 million and a Daily Traded Value greater than US$1.0 million.
- Redemption Triggers: In the event of a Change of Control, De-Listing, or Free Float Event, the Notes are redeemable at 120% of the principal amount plus a Make-Whole Premium.
Use of Proceeds, Outlook, and Risks
Management intends to use the aggregate proceeds for the following purposes:
- Launching commercialization activities in the United States and advancing the Genio system in initial target markets outside the U.S.
- Gathering clinical data and supporting physician-initiated research for OSA treatments.
- Financing R&D for Genio system upgrades, redesigning for manufacturability, and cost reduction.
- Building a pipeline of new technologies and exploring collaborations in OSA monitoring and diagnostics.
- General corporate purposes, including working capital, capital expenditures, and potential acquisitions.
Risks and Contingencies: The transactions are subject to customary closing conditions. The Second Tranche Notes issuance is specifically contingent on market capitalization and trading volume thresholds. The filing includes standard forward-looking statement disclaimers regarding the completion of these offerings and the achievement of business goals.
Investor Verification Checklist
- Verify the closing of the Private Placement and RDO on or about November 18, 2025.
- Confirm whether the Company meets the market capitalization (€240.0 million) and daily traded volume (US$1.0 million) thresholds required to trigger the Second Tranche Notes issuance.
- Review the specific terms of the Bond Instrument and Subscription Agreements once filed as exhibits to understand the exact mechanics of the share settlement option for amortization payments.
- Monitor the Company's ability to service the 6.5% interest and amortization payments on the Notes, particularly if cash flow is prioritized for commercialization.
- Assess the dilution impact of the Private Placement, RDO, and potential conversion/amortization shares on existing shareholders.